---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-069381"
form_type: "8-K"
ticker: "LITS"
cik: "0001262104"
company_name: "Lite Strategy, Inc."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T14:44:11.943218+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MEI Pharma reports clinical data on oral CDK9 inhibitor voruciclib at ASH2023; safety profile well-tolerated

## Summary
- Voruciclib monotherapy up to 200 mg on intermittent schedule well-tolerated; no DLTs. Common AEs: diarrhea, nausea, anemia, fatigue.
- On-target Mcl-1 and RNA Pol II p-S2 reductions demonstrated in correlative pharmacodynamic studies.
- In AML monotherapy: 1 patient achieved morphologic leukemia-free state; 9 had stable disease (2 for ≥3 months).
- In B-cell malignancies: 4 patients had stable disease with tumor size decrease.
- Combination with venetoclax ongoing; no DLTs or overlapping toxicity; anti-tumor activity observed with multiple patients on therapy ≥4 months.

## SEC filing metadata
- accession: 0000950170-23-069381
- form_type: 8-K
- ticker: LITS
- cik: 0001262104
- company_name: Lite Strategy, Inc.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1262104/000095017023069381/0000950170-23-069381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1262104/000095017023069381/meip-20231211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-069381
- JSON: https://secwatch.observer/filing/0000950170-23-069381.json
- Plain text: https://secwatch.observer/filing/0000950170-23-069381.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.